Cellphire Therapeutics, Inc.
Cellphire Therapeutics is a clinical stage biotechnology company focused on developing next-generation allogeneic cellular therapeutics to address significant unmet needs in hemostatic treatments. With innovative products like Thrombosomes® and Cryopreserved Platelets, Cellphire aims to revolutionize bleeding management and improve patient outcomes across various clinical settings.
Cellphire Therapeutics, Inc.
9430 Key West Avenue, Suite 250, Rockville, MD 20850
What We Do
A stabilized platelet-derived biologic designed for use in hospital operating rooms, currently in Phase 2 clinical trials.
A product utilizing cryopreservation of platelets, addressing availability challenges for rural and field hospitals, targeting BLA in 2027, and currently in Phase 2/3 clinical trials.
Application Area
Battlefield Resuscitation
Biologics
Key People
Chief Medical Officer
Chief Scientific Officer
Vice President of Finance, Treasurer and Controller
Vice President of Business Operations
VP, New Product Development & Capital Support
News & Updates
Dr. Damien Bates joins Cellphire as Chief Medical Officer, bringing extensive experience in clinical development and strategic leadership.
Cellphire acknowledges the completion of enrollment in the study of Thrombosomes® for Acute Aortic Dissections at Rigshospitalet, Denmark.
Dr. Ed Coles joins Cellphire as Vice President of Program Management and Product Development Lead.
Cellphire's commitment to innovation and contributions to the life sciences industry were recognized with this nomination.
Cellphire was issued a patent covering innovation in the use of Freeze-Dried Platelet-Derived Hemostat Technology loaded with anti-cancer compounds.
Patent covering the use of Freeze-Dried Platelet-Derived Hemostat Technology loaded with anti-cancer compounds.